Novo touts SGLT2-topping data for blockbuster Victoza

SGLT2 drugs may be in the diabetes spotlight thanks to recent data showing that one of them--Eli Lilly ($LLY) and Boehringer Ingelheim's Jardiance--could cut cardiovascular risks. But Novo Nordisk ($NVO), maker of GLP-1 superstar Victoza, is striking back with some new data of its own. The company has rolled out a new meta-analysis showing that its therapy beat out SGLT2s at reducing the blood sugar metric HbA1c. More from FiercePharmaMarketing

Suggested Articles

With generics at the gates, Novartis’ Gilenya secured a breath of fresh air—and protection for its blockbuster sales—with a federal injunction.

Akorn has been slammed with another FDA warning letter even as it is in the process of renegotiating its loans with lenders.

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.